※一部利用できない機能があります
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations
- フォーマット:
- 論文
- 責任表示:
- Yamada, Tadaaki ; Takeuchi, Shinji ; Fujita, Naoya ; Nakamura, Akito ; Wang, Wei ; Li, Qi ; Oda, Makoto ; Mitsudomi, Tetsuya ; Yatabe, Yasushi ; Sekido, Yoshitaka ; Yoshida, Junji ; Higashiyama, Masahiko ; Noguchi, Masayuki ; Uehara, Hisanori ; Nishioka, Yasuhiko ; Sone, Saburo ; Yano, Seiji
- 言語:
- 英語
- 出版情報:
- Nature Publishing Group, 2013-09-12
- 著者名:
- 掲載情報:
- Oncogene
- ISSN:
- 0950-9232
- 巻:
- 32
- 通号:
- 37
- 開始ページ:
- 4427
- 終了ページ:
- 4435
- バージョン:
- author
- 概要:
- Despite initial dramatic response, epidermal growth factor receptor (EGFR) mutant lung cancer patients always acquire resistance to EGFR-tyrosine kinase inhibitors (TKIs). Gatekeeper T790M mutation in EGFR is the most prevalent genetic alte … ration underlying acquired resistance to EGFR-TKI, and EGFR mutant lung cancer cells are reported to be addictive to EGFR/Akt signaling even after acquired T790M mutation. Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinositide 3-kinase)/PDK1 (3-phosphoinositide-dependent protein kinase)/Akt that determines receptor signal selectivity for non-mutated EGFR, and assessed its role in EGFR mutant lung cancer with or without gatekeeper T790M mutation. Cell line-based assays showed that Aki1 constitutively associates with mutant EGFR in lung cancer cells with (H1975) or without (PC-9 and HCC827) T790M gatekeeper mutation. Silencing of Aki1 induced apoptosis of EGFR mutant lung cancer cells. Treatment with Aki1 siRNA dramatically inhibited growth of H1975 cells in a xenograft model. Moreover, silencing of Aki1 further potentiated growth inhibitory effect of new generation EGFR-TKIs against H1975 cells in vitro. Aki1 was frequently expressed in tumor cells of EGFR mutant lung cancer patients (53/56 cases), including those with acquired resistance to EGFR-TKI treatment (7/7 cases). Our data suggest that Aki1 may be a critical mediator of survival signaling from mutant EGFR to Akt, and may therefore be an ideal target for EGFR mutant lung cancer patients, especially those with acquired EGFR-TKI resistance due to EGFR T790M gatekeeper mutation.Oncogene advance online publication, 8 October 2012; doi:10.1038/onc.2012.446.<br />In Press → 発行後6か月より全文を公開. 続きを見る
- URL:
- http://hdl.handle.net/2297/32869
類似資料:
American Association for Cancer Research |
金沢大学がん研究所 = Kanazawa University Cancer Research Institute |
American Association for Cancer Research |
Japanese Cancer Association = 日本癌学会 / John Wiley & Sons |
金沢大学がん研究所 = Kanazawa University Cancer Research Institute | |
金沢大学がん研究所 = Kanazawa University Cancer Research Institute |
10
論文
Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma
The Japanese Cancer Association = 日本癌学会 / Blackwell Publishing Ltd |
金沢大学がん研究所 = Kanazawa University Cancer Research Institute | |
金沢大学がん研究所 = Kanazawa University Cancer Research Institute |